SG11201908998XA - Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule - Google Patents

Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule

Info

Publication number
SG11201908998XA
SG11201908998XA SG11201908998XA SG11201908998XA SG 11201908998X A SG11201908998X A SG 11201908998XA SG 11201908998X A SG11201908998X A SG 11201908998XA SG 11201908998X A SG11201908998X A SG 11201908998XA
Authority
SG
Singapore
Prior art keywords
international
compositions
methods
progastrin
prostate cancer
Prior art date
Application number
Inventor
Alexandre Prieur
Original Assignee
Progastrine Et Cancers S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S A R L filed Critical Progastrine Et Cancers S A R L
Publication of SG11201908998XA publication Critical patent/SG11201908998XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT omits I iolo MEW 0011011 001110#011 (10) International Publication Number WO 2018/178363 Al (51) International Patent Classification: C07K 16/28 (2006.01) GO1N 33/574 (2006.01) C07K 16/30 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2018/058344 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305381.0 30 March 2017 (30.03.2017) EP (71) Applicant: PROGASTRINE ET CANCERS S.A R.L. [LU/LU]; 11, C6te d'Eich, L - 1450 LUXEMBOURG (LU). (72) Inventor: PRIEUR, Alexandre; 24 me de la Cavalerie, 34000 MONTPELLIER (FR). (74) Agent: REGIMBEAU; 20, rue de Chazelles, 75847 PARIS CEDEX 17 (FR). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) W O 20 18/ 17 8363 Al Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: COMPOSITIONS AND METHODS FOR DETECTING AND TREATING PROSTATE CANCER USING PROGASTRIN BINDING MOLECULE (57) : The present invention relates to compositions and methods for the prevention or the treatment of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.
SG11201908998X 2017-03-30 2018-03-30 Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule SG11201908998XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305381 2017-03-30
PCT/EP2018/058344 WO2018178363A1 (en) 2017-03-30 2018-03-30 Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule

Publications (1)

Publication Number Publication Date
SG11201908998XA true SG11201908998XA (en) 2019-10-30

Family

ID=58501413

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908998X SG11201908998XA (en) 2017-03-30 2018-03-30 Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
SG11201908997U SG11201908997UA (en) 2017-03-30 2018-03-30 Compositions and methods for detecting prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201908997U SG11201908997UA (en) 2017-03-30 2018-03-30 Compositions and methods for detecting prostate cancer

Country Status (12)

Country Link
US (2) US11614448B2 (en)
EP (2) EP3601343B1 (en)
JP (2) JP7156622B2 (en)
KR (2) KR102351556B1 (en)
CN (2) CN110662769B (en)
AU (2) AU2018242156B2 (en)
BR (2) BR112019020414A2 (en)
CA (2) CA3058263C (en)
EA (2) EA201992316A1 (en)
ES (2) ES2904939T3 (en)
SG (2) SG11201908998XA (en)
WO (2) WO2018178352A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2920283T3 (en) * 2017-12-05 2022-08-02 Progastrine Et Cancers S A R L Combination therapy between an antiprogastrin antibody and immunotherapy to treat cancer
JP7338128B2 (en) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル Radiolabeled progastrin in cancer diagnosis
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
US20200400675A1 (en) 2018-02-27 2020-12-24 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
CN111518908B (en) * 2020-05-18 2023-10-17 奥尔文泰生物科技(杭州)有限公司 Urine prostate cancer marker combination and application thereof in preparation of accurate diagnostic reagent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
DE69431114T2 (en) * 1993-04-27 2003-03-13 United Biomedical Inc IMMUNOGENEOUS LHRH PEPTIDE CONSTRUCTION AND SYNTHETIC, UNIVERSAL IMMUNE STIMULATORS AS VACCINE
JP4312259B2 (en) 1995-04-27 2009-08-12 アムジェン フレモント インク． Human antibodies derived from immunized XenoMouse
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR100643058B1 (en) 1996-12-03 2006-11-13 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DK0970126T3 (en) 1997-04-14 2001-08-13 Micromet Ag Hitherto unknown method for the preparation of anti-human antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU9689398A (en) * 1997-10-07 1999-04-27 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
NZ517331A (en) * 1999-07-29 2004-02-27 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
JP2003111595A (en) * 2001-06-25 2003-04-15 Kyogo Ito Tumor antigen
JP2003261460A (en) * 2002-03-08 2003-09-16 Kyowa Hakko Kogyo Co Ltd Diagnostic agent and treating agent for lung selective cancer metastasis
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
AU2005254058A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for the treatment of human cancer
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
ES2364185T3 (en) * 2005-04-13 2011-08-26 Advanced Life Science Institute, Inc. ANTIBODY DIRECTED AGAINST A PRECURSOR OF A GASTRINE RELEASE PEPTIDE AND ITS USE.
AR078659A1 (en) * 2009-10-16 2011-11-23 Biorealites S A MONOCLONAL ANTIBODIES AGAINST HUMAN PROGASTRINE AND ITS USES
US20130095503A1 (en) * 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
BR112012024036B1 (en) 2010-03-24 2020-03-03 Les Laboratoires Servier COLORRETAL AND GASTROINTESTINAL CANCER PROPHYLAXIS
US10533050B2 (en) 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy
AU2014351611B2 (en) * 2013-11-19 2020-04-23 Janssen Biotech, Inc. Humanised anti kallikrein-2 antibody
WO2016066671A1 (en) * 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
TW201639891A (en) 2015-03-10 2016-11-16 索倫多醫療公司 Antibody therapeutics that bind PSMA
BR112018013269A2 (en) 2015-12-31 2018-12-11 Syncerus S A R L compositions and methods for cancer risk assessment

Also Published As

Publication number Publication date
JP7156622B2 (en) 2022-10-19
CA3058267A1 (en) 2018-10-04
BR112019020413A2 (en) 2020-06-09
BR112019020414A2 (en) 2020-06-09
KR20190141144A (en) 2019-12-23
AU2018242152B2 (en) 2022-05-12
CN110945025A (en) 2020-03-31
ES2904939T3 (en) 2022-04-06
CA3058263A1 (en) 2018-10-04
KR102317805B1 (en) 2021-10-27
JP2020515580A (en) 2020-05-28
CA3058263C (en) 2023-08-01
ES2921775T3 (en) 2022-08-31
JP7071994B2 (en) 2022-05-19
CN110662769A (en) 2020-01-07
CN110662769B (en) 2023-10-20
SG11201908997UA (en) 2019-10-30
US20200200751A1 (en) 2020-06-25
KR20190133219A (en) 2019-12-02
EP3601343B1 (en) 2022-05-04
EP3601343A1 (en) 2020-02-05
EP3601347B1 (en) 2021-11-03
CN110945025B (en) 2023-11-03
EA201992316A1 (en) 2020-03-05
WO2018178363A1 (en) 2018-10-04
EP3601347A1 (en) 2020-02-05
US11644468B2 (en) 2023-05-09
AU2018242152A1 (en) 2019-10-17
KR102351556B1 (en) 2022-01-14
US20210087265A1 (en) 2021-03-25
WO2018178352A1 (en) 2018-10-04
CA3058267C (en) 2023-07-25
EA201992318A1 (en) 2020-03-05
AU2018242156B2 (en) 2021-07-29
US11614448B2 (en) 2023-03-28
AU2018242156A1 (en) 2019-10-31
JP2020515875A (en) 2020-05-28

Similar Documents

Publication Publication Date Title
SG11201908998XA (en) Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201808125RA (en) Methods for solid tumor treatment
SG11201805141QA (en) Compositions and methods for detecting and treating gastric cancer
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908888VA (en) Compositions and methods for treating lung cancer
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201907693VA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900361RA (en) Methods of treating prostate cancer